

Celltrion and Lonza Sign Contract to Manufacture Remsima Drug Substance

- Celltrion contracts Remsima drug substance manufacturing to Lonza to satisfy increasing global demand for biosimilars
- Lonza's biologics facility in Singapore to cover EU and US market needs
- Partnership will provide cost-effective biologics for greater patient benefit worldwide

Quote from Woo Sung Kee, CEO, Celltrion:

"The stable manufacturing system and superb product quality management were the most important factors in choosing our partner Lonza. It will be a great opportunity to expand our global supplying capacity to provide the greater healthcare benefit through these cost-effective biologics since demand of biosimilars is increasing worldwide."

Quote from Marc Funk, CEO, Lonza Group:

"We will be working in close partnership with Celltrion to ensure it has access to the flexible capacity and agile teams it needs to respond to evolving market demand for Remsima. In the competitive biosimilars market, we can support Celltrion with our experience in biologics as it enables broader patient access to affordable, life-changing therapies."

Incheon, South Korea and Basel, Switzerland, 3 August 2019 – Celltrion and Lonza announced a contract manufacturing agreement to produce drug substance for Remsima, a biosimilar approved by the EMA and the FDA for a number of autoimmune diseases including Crohn's disease and rheumatoid arthritis.

To complement its existing capacity of 190,000L of drug substance per year from two plants in Korea, Celltrion has looked to Lonza to diversify its supply base and meet the increasing demands of the biosimilar market.

The Remisma drug substance will be produced in Lonza's commercial facility in Singapore to cover market needs in Europe and North America. Over the first quarter of 2019, the two companies worked together on the validation process at Lonza's Singapore manufacturing facility and have submitted the products produced there for approval by the European Medicines Agency (EMA). Continuing the collaboration, the two companies will also seek Food and Drug Administration (FDA) approval.

About Lonza

Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com.

About Celltrion

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in the research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics.

Celltrion received FDA and EC's approval for INFLECTRA® and Remsima®, respectively, which is the world's first mAb biosimilar to receive approval from a regulatory agency in a developed country. For more information, visit www.celltrion.com.

Lonza Contact Details

Dirk Oehlers

Investor Relations

Tel +41 61 316 8540

dirk.oehlers@lonza.com

Dr. Kristin Koehler

Investor Relations

Tel +41 61 316 8782

kristin.koehler@lonza.com

Dr. Sanna Fowler

Head of External Communications

Tel +41 61 316 8929

sanna.fowler@lonza.com

Celltrion Contact Details

Kyungchul Park

Tel +82 32 850 5320

kyungchul.park@celltrion.com

Tae-Gyun Kim

Tel +82 32 850 5136

Taegyun.kim@celltrion.com

Lonza Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.